Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
UVV Universal Corp
LNC Lincoln National Corp
FMCCG Federal Home Loan Mortgage Corp
CSAN Cosan SA
SAIC Science Applications International Corp
MUR Murphy Oil Corp
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
CODI Compass Diversified Holdings
MDRRP Medalist Diversified Reit Inc
Go


Based in Canada
Company profile

Cybin Inc. is a Canada-based biopharmaceutical company. The Company is focused on progressing psychedelic therapeutics. The Company operates business through its subsidiary Cybin Corp. The Company operates through two segments: Serenity Life Sciences Inc. (Serenity Life) and Cybin US Holdings Inc. (Cybin U.S.) that focus on the research and development of psychedelic pharmaceutical products, and Natures Journey Inc. that focuses on consumer mental wellness, including non-psychedelic nutraceutical products. The Company focuses on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols. Its subsidiaries include Natures Journey Inc. (Journey), Serenity Life Sciences Inc. (Serenity), Cybin US Holdings Inc. (Cybin US), Adelia Therapeutics Inc. (Adelia) and Cybin IRL Limited.

Closing Price
$1.01
Day's Change
-0.01 (-0.98%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.09
Day's Low
1.00
Volume
(Below Average)
Volume:
741,417

10-day average volume:
923,900
741,417

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, January 27, 2022
Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary...(BusinessWire)

Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" today announced that it will report financial results for its third quarter ended December...(BusinessWire)

January 11, 2022
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored...(BusinessWire)

January 06, 2022
Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin...(BusinessWire)

December 22, 2021
Cybin Provides 2021 Year End Summary

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021...(BusinessWire)

December 21, 2021
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate...(BusinessWire)

December 16, 2021
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies

Drugs like ketamine and psilocybin -- the active ingredient in magic mushrooms -- are showing real promise in addressing mental health disorders. More and more psychedelic-assisted psychotherapy clinics, are focusing on the whole patient experience...(PR Newswire)

December 15, 2021
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders

Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) (" Cybin" or the " Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics (TM)" today announced that it has been awarded a Notice of Allowance from the U.S. Patent and...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.